Chengyi Pharmaceutical released its 2026 half-year report. First-half net profit attributable to the parent was 94.87 million yuan, down 15.6% year on year. Operating revenue was 432 million yuan, up 3.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 92.45 million yuan, down 16.8% year on year. Net operating cash flow was 141 million yuan, down 0.3% year on year. Earnings per share were 0.207 yuan. In the second quarter, operating revenue was 231 million yuan, down 0.1% year on year, and net profit attributable to the parent was 50.58 million yuan, down 24.1% year on year. As of the end of the second quarter, total assets were 1.751 billion yuan, up 2.9% from the end of the previous year, and net assets attributable to the parent were 1.419 billion yuan, up 2.1%. The company said the pharmaceutical industry is under overall pressure but market size is still growing. Its core glucosamine product business showed outstanding performance in market expansion and self-sufficiency in raw materials, and its health product Yuzhixin fish oil soft capsules received approval. The company is also responding to challenges by strengthening in-house production of active pharmaceutical ingredients, optimizing channels, disposing of loss-making subsidiaries, and implementing an employee stock ownership plan.
Zhejiang Cheng Yi Pharmaceutical Co LtdFirst-half net profit fell 15.6% year on year, with Q2 profit down 24.1%.
